Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
A. Chazot, C. Zimberger, M. Feracci, A. Moussa, S. Good, J.-P. Sommadossi, K. ALVAREZ, F. Ferron, B. Canard
This paper reveals the activation pathway of bemnifosbuvir to its active form AT-9010, showing the required enzymes and structural insights into the process.
bioRxiv · Feb 16, 2024 · PreprintBiochemistry
A. Moussa, S. Nones, P. E. Vannucchi, G.-R. Shahzad, J. Dittmer, E. Corretto, M. Schebeck, M. Faccoli, A. Battisti, C. Stauffer, H. Schuler
This study analyzes the bacterial communities of the European spruce bark beetle across different populations and seasons, finding variation in community structure but no difference between epidemic and endemic populations.
bioRxiv · Apr 28, 2023Ecology
K. Lin, S. S. Good, J. G. Julander, A. Weight, A. Moussa
This paper demonstrates that AT-752, a prodrug of a guanosine nucleotide analog, reduces YFV viremia and liver damage in hamsters and improves survival rates.
bioRxiv · Oct 25, 2021Pharmacology & Toxicology
A. Shannon, V. Fattorini, B. Sama, B. Selisko, M. Feracci, C. Falcou, P. Gauffre, P. El Kazzi, E. Decroly, N. Rabah, K. Toulon, C. Eydoux, J.-C. Guillemot, M. Noel, F. Debart, , B. Canard
This paper identifies a protein-priming mechanism for SARS-CoV RNA synthesis and shows that AT-527 inhibits this process by targeting both NiRAN and RdRp domains.
bioRxiv · Mar 23, 2021Biochemistry
S. S. Good, J. Westover, K. H. Jung, P. La Colla, G. Collu, A. Moussa, B. Canard, J.-P. Sommadossi
The paper reports that AT-511, a form of AT-527, is a potent in vitro inhibitor of SARS-CoV-2 replication with low cytotoxicity.
bioRxiv · Aug 11, 2020 · PreprintPharmacology & Toxicology